235 related articles for article (PubMed ID: 27484624)
1. Synthetic and Natural Lipase Inhibitors.
Bialecka-Florjanczyk E; Fabiszewska AU; Krzyczkowska J; Kurylowicz A
Mini Rev Med Chem; 2018; 18(8):672-683. PubMed ID: 27484624
[TBL] [Abstract][Full Text] [Related]
2. Polyphenolic Compounds as Pancreatic Lipase Inhibitors.
Buchholz T; Melzig MF
Planta Med; 2015 Jul; 81(10):771-83. PubMed ID: 26132857
[TBL] [Abstract][Full Text] [Related]
3. Covalent inhibition of digestive lipases by chiral phosphonates.
Cavalier JF; Buono G; Verger R
Acc Chem Res; 2000 Sep; 33(9):579-89. PubMed ID: 10995195
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic lipase inhibitors from natural sources: unexplored potential.
Birari RB; Bhutani KK
Drug Discov Today; 2007 Oct; 12(19-20):879-89. PubMed ID: 17933690
[TBL] [Abstract][Full Text] [Related]
5. Using the reversible inhibition of gastric lipase by Orlistat for investigating simultaneously lipase adsorption and substrate hydrolysis at the lipid-water interface.
Bénarouche A; Point V; Carrière F; Cavalier JF
Biochimie; 2014 Jun; 101():221-31. PubMed ID: 24508576
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease.
Du J; Wang Z
Med Hypotheses; 2009 Nov; 73(5):662-3. PubMed ID: 19505770
[TBL] [Abstract][Full Text] [Related]
7. Lipases and lipolysis in the human digestive tract: where do we stand?
Armand M
Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):156-64. PubMed ID: 17285003
[TBL] [Abstract][Full Text] [Related]
8. Nanostructured clay particles supplement orlistat action in inhibiting lipid digestion: An in vitro evaluation for the treatment of obesity.
Joyce P; Dening TJ; Meola TR; Gustafsson H; Kovalainen M; Prestidge CA
Eur J Pharm Sci; 2019 Jul; 135():1-11. PubMed ID: 31067495
[TBL] [Abstract][Full Text] [Related]
9. Mode of action of orlistat.
Guerciolini R
Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S12-23. PubMed ID: 9225172
[TBL] [Abstract][Full Text] [Related]
10. First clinical studies with orlistat: a short review.
Drent ML; van der Veen EA
Obes Res; 1995 Nov; 3 Suppl 4():623S-625S. PubMed ID: 8697067
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
Carrière F; Renou C; Ransac S; Lopez V; De Caro J; Ferrato F; De Caro A; Fleury A; Sanwald-Ducray P; Lengsfeld H; Beglinger C; Hadvary P; Verger R; Laugier R
Am J Physiol Gastrointest Liver Physiol; 2001 Jul; 281(1):G16-28. PubMed ID: 11408251
[TBL] [Abstract][Full Text] [Related]
12. Development and Optimization of a High-Throughput Screening Assay for Rapid Evaluation of Lipstatin Production by Streptomyces Strains.
Híreš M; Rapavá N; Šimkovič M; Varečka Ľ; Berkeš D; Kryštofová S
Curr Microbiol; 2018 May; 75(5):580-587. PubMed ID: 29256008
[TBL] [Abstract][Full Text] [Related]
13. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine.
Sternby B; Hartmann D; Borgström B; Nilsson A
Clin Nutr; 2002 Oct; 21(5):395-402. PubMed ID: 12381337
[TBL] [Abstract][Full Text] [Related]
14. Lipases at interfaces: a review.
Reis P; Holmberg K; Watzke H; Leser ME; Miller R
Adv Colloid Interface Sci; 2009; 147-148():237-50. PubMed ID: 18691682
[TBL] [Abstract][Full Text] [Related]
15. Antiobesity potential of ursolic acid stearoyl glucoside by inhibiting pancreatic lipase.
Kazmi I; Afzal M; Rahman S; Iqbal M; Imam F; Anwar F
Eur J Pharmacol; 2013 Jun; 709(1-3):28-36. PubMed ID: 23500199
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of grape seed extract on lipases.
Moreno DA; Ilic N; Poulev A; Brasaemle DL; Fried SK; Raskin I
Nutrition; 2003 Oct; 19(10):876-9. PubMed ID: 14559324
[TBL] [Abstract][Full Text] [Related]
17. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients.
Zhi J; Mulligan TE; Hauptman JB
J Clin Pharmacol; 1999 Jan; 39(1):41-6. PubMed ID: 9987699
[TBL] [Abstract][Full Text] [Related]
18. Molecular recognition between pancreatic lipase and natural and synthetic inhibitors.
Bello M; Basilio-Antonio L; Fragoso-Vázquez J; Avalos-Soriano A; Correa-Basurto J
Int J Biol Macromol; 2017 May; 98():855-868. PubMed ID: 28212930
[TBL] [Abstract][Full Text] [Related]
19. Targeting obesity with plant-derived pancreatic lipase inhibitors: A comprehensive review.
Rajan L; Palaniswamy D; Mohankumar SK
Pharmacol Res; 2020 May; 155():104681. PubMed ID: 32045666
[TBL] [Abstract][Full Text] [Related]
20. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity.
Shi Y; Burn P
Nat Rev Drug Discov; 2004 Aug; 3(8):695-710. PubMed ID: 15286736
[No Abstract] [Full Text] [Related]
[Next] [New Search]
